SC-262

N/A

Report date: 2025/03/21 11:28:27

Base Information

Drug NameSC-262
Drug Alias NameAllogeneic CD22-directed CAR T Cell TherapySC-262SC-263
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSana Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesSana Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A